GP
ICPT

GLG Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

GLG Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,479
Closed -$370K – 514
2015
Q4 		$370K Sell
2,479
-15,073
-86% -$2.55M 0.01% 392
2015
Q3 		$2.91M Sell
17,552
-2,739
-13% -$603K 0.08% 245
2015
Q2 		$4.9M Buy
20,291
+15,554
+328% +$4.14M 0.13% 181
2015
Q1 		$1.34M Sell
4,737
-21,860
-82% -$4.73M 0.04% 281
2014
Q4 		$4.15M Buy
+26,597
New +$4.91M 0.12% 176

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GLG Partners's ICPT Position: Q1 2016 in Review

GLG Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2016, closing a stake of 2,479 shares — an estimated $370K sold.

GLG Partners first reported a position in ICPT in Q4 2014 and held it in 5 quarters. The position peaked at $4.9M in Q2 2015. 160 funds tracked by Wall St. Rank hold ICPT as of Q1 2016.

  • GLG Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • GLG Partners sold 2,479 Intercept Pharmaceuticals, Inc. shares in Q1 2016, an estimated $370K.
  • GLG Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
  • GLG Partners's Intercept Pharmaceuticals, Inc. position peaked at $4.9M in Q2 2015.
  • 160 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2016.

Based on GLG Partners's 13F filing for Q1 2016, filed 16 May 2016.